



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

Extracting value from Artificial Intelligence in Medicines Regulation

Regulatory Science Network Netherlands – June 2024


Luis Pinheiro, EMA, Data Analytics and Methods Taskforce

An agency of the European Union





Content





Intro to AI & the promise of AI



Brief introduction to AI

AI is a catch-all term for a collection of novel digital technologies and methods

Allow machines to extract rules from data (*i.e., learn*)

Predict, classify or cluster similar patterns using those rules or execute autonomous actions

AI is data-driven

1

Needs data

(data protection
/security)

2

**Typically* needs
supervision**

(establish ground
truth)

3

**Predicts/
classifies the past**

(performance drops)

4

**Bias in data
become rules**


(ethical issues)

5

**Needs Human
intelligence**

(design issues)

Artificial intelligence | Types of AI



The Promise of AI | AI promise across the medicine lifecycle

Greater efficiency /productivity



- Automate processes
 - Address scalability issues
 - Leverage personal assistants (chatbots)
- Do more things, faster*

Reduce error



- Facilitate access to information
 - Reduce human cognitive load
- Provide information at the fingertip*

Expose data



- Transform text data into structured data
 - Reduce dimensionality of data
 - Imputation of missing data
- Structure and summarise information*

Expand insights



- Probabilistic phenotyping
 - Synthetic control arms
 - Clinical prediction modelling
 - Confounding adjustment
 - Digital endpoints
 - Heterogeneity of treatment effects
- Predict probability of events*

Safe and responsible use | AI can be wrong

describe the broken twig syndrome




The "broken twig syndrome" is a metaphor often used in psychology and counseling to describe a phenomenon where individuals become overly focused on small problems or setbacks, to the point where they exaggerate their significance and let them overshadow everything else. Just like how a twig breaking in a forest might capture someone's attention disproportionately, this syndrome suggests that people can become fixated on minor issues, ignoring the bigger picture and positive aspects of their lives. It's often associated with pessimism, anxiety, and a tendency to catastrophize. Therapeutic interventions for this syndrome typically involve helping individuals gain perspective, develop resilience, and cultivate a more balanced outlook.





Safe and responsible use | AI not always needed





Drivers for change



AI in Healthcare | Regulatory Drivers



Regulatory
submissions



Process
Analytics



Healthcare
Analytics



AI in Healthcare | Regulatory Drivers



Regulatory
submissions

**Regulate applications of
AI** in medicines to help
create value for public health



Process
Analytics



Healthcare
Analytics



AI in Healthcare | Regulatory Drivers



Regulatory
submissions



Process
Analytics

Improve **efficiency** by
automating and digitalizing
processes



Healthcare
Analytics



AI in Healthcare | Regulatory Drivers



Regulatory
submissions



Process
Analytics



Healthcare
Analytics

**Structure information and
increase insights** into data
to inform decision-making



Internal Drivers

Process analytics and healthcare data analytics



AI at EMA | Set up

Digital Innovation Lab (DigiLab)

Established 2021 to accelerate digital innovation and experimentation

Analytics Centre of Excellence

Explore analytics, AI, ML and robotics to
**build pragmatic solutions and experiment with
new technology**

-- Process analytics --

Health Data Lab (pilot)

Develop innovative analytics to **extract insights from
healthcare data**, to provide
answers/recommendations and maximise intelligence

-- Healthcare data analytics --

Infrastructure


Information Processing and Analytics

Improve the organisation's performance through streamlining information processing across the regulatory lifecycle.

-- Data analytics tools and platforms --



DigiLab | Digital innovation framework





AI experimentation | Examples



Literature screening

Use of LLMs to identify abstracts with information on the occurrence of adverse reactions



Extraction of ADRs from SmPCs

(semi) Automated extraction of ADRs from product information



Automated adjudication of ADRs

Automated adjudication of ADRs



Improve signal detection with previous reviews

Using signal reviews to improve signal detection



AI experimentation | Examples



Literature screening

Use of LLMs to identify abstracts with information on the occurrence of adverse reactions



Extraction of ADRs from SmPCs

(semi) Automated extraction of ADRs from product information



Automated adjudication of ADRs

Automated adjudication of ADRs



Improve signal detection with previous reviews

Using signal reviews to improve signal detection



AI experimentation | Examples



Literature screening

Use of LLMs to identify abstracts with information on the occurrence of adverse reactions



Extraction of ADRs from SmPCs

(semi) Automated extraction of ADRs from product information



Automated adjudication of ADRs

Automated adjudication of ADRs



Improve signal detection with previous reviews

Using signal reviews to improve signal detection



AI experimentation | Examples



Literature screening

Use of LLMs to identify abstracts with information on the occurrence of adverse reactions



Extraction of ADRs from SmPCs

(semi) Automated extraction of ADRs from product information



Automated adjudication of ADRs

Automated adjudication of ADRs



Improve signal detection with previous reviews

Using signal reviews to improve signal detection



External Drivers

Regulate AI

Guidance | AI Reflection Paper



1 13 July 2023
2 EMA/CHMP/CVMP/83833/2023
3 Committee for Medicinal Products for Human Use (CHMP)
4 Committee for Medicinal Products for Veterinary Use (CVMP)

5 Reflection paper on the use of Artificial Intelligence (AI) in
6 the medicinal product lifecycle
7 Draft

Draft agreed by Committee for Medicinal Products for Human Use (CHMP) Methodology Working Party	July 2023
Draft adopted by CVMP for release for consultation	13 July 2023
Draft adopted by CHMP for release for consultation	10 July 2023
Start of public consultation	19 July 2023
End of consultation (<i>deadline for comments</i>)	31 December 2023
Comments should be provided using this EUSurvey form . For any technical issues, please contact the EUSurvey Support .	
Keywords	<i>Artificial intelligence, AI, machine learning, ML, regulatory, medicine, human medicinal product, veterinary medicinal product</i>

Reflection paper on the use of AI in the medicinal product lifecycle

Table of contents

1. Introduction	3
2. Discussion	4
2.1. General considerations	4
2.2. AI in the lifecycle of medicinal products	4
2.2.1. Drug discovery	4
2.2.2. Non-clinical development	5
2.2.3. Clinical trials	5
2.2.4. Precision medicine	6
2.2.5. Product information	7
2.2.6. Manufacturing	7
2.2.7. Post-authorisation phase	7
2.3. Regulatory interactions	7
2.4. Technical aspects	8
2.4.1. Data acquisition and augmentation	8
2.4.2. Training, validation, and test data	9
2.4.3. Model development	9
2.4.4. Performance assessment	9
2.4.5. Interpretability and explainability	10
2.4.6. Model deployment	10
2.5. Governance	10
2.6. Data protection	11
2.7. Integrity aspects	11
2.8. Ethical aspects and trustworthy AI	11
3. Conclusion	12




Bringing it all together

Enabling responsible and safe use of AI for the benefit of public and animal health



Multi-annual AI workplan 2023-2028

● Events Timeframe





Any questions?

Further information

luís.pinheiro@ema.europa.eu

Official address Domenico Scarlattilaan 6 • 1083 HS Amsterdam • The Netherlands

Telephone +31 (0)88 781 6000

Send us a question Go to www.ema.europa.eu/contact

Follow us on  **@EMA_News**